Acrux Limited (ACR.AX)
AUD 0.02
(4.55%)
AUD 0.02
(4.55%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | -1.28 Million AUD | -165.98% |
| 2023 | 1.94 Million AUD | 141.83% |
| 2022 | -4.65 Million AUD | 38.72% |
| 2021 | -7.59 Million AUD | -101.94% |
| 2020 | -3.75 Million AUD | 16.32% |
| 2019 | -4.49 Million AUD | -5447.62% |
| 2018 | 84 Thousand AUD | -99.59% |
| 2017 | 20.55 Million AUD | -21.35% |
| 2016 | 26.13 Million AUD | 9.81% |
| 2015 | 23.8 Million AUD | -53.58% |
| 2014 | 51.27 Million AUD | 241.48% |
| 2013 | 15.01 Million AUD | 75.91% |
| 2012 | 8.53 Million AUD | -90.14% |
| 2011 | 86.59 Million AUD | 63.41% |
| 2010 | 52.99 Million AUD | 8052.46% |
| 2009 | 650 Thousand AUD | -83.08% |
| 2008 | 3.84 Million AUD | 32.59% |
| 2007 | 2.89 Million AUD | 460.35% |
| 2006 | 517 Thousand AUD | -80.93% |
| 2005 | 2.71 Million AUD | -16.96% |
| 2004 | 3.26 Million AUD | 337.46% |
| 2003 | 746.3 Thousand AUD | 36.33% |
| 2002 | 547.44 Thousand AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -2.27 Million AUD | 0.0% |
| 2024 FY | -4.67 Million AUD | -340.08% |
| 2024 Q4 | -618 Thousand AUD | 0.0% |
| 2023 FY | 1.94 Million AUD | 141.83% |
| 2023 Q2 | -2.02 Million AUD | 0.0% |
| 2023 Q4 | 4.15 Million AUD | 0.0% |
| 2022 Q4 | -2.04 Million AUD | 0.0% |
| 2022 Q2 | -2.61 Million AUD | 0.0% |
| 2022 FY | -4.65 Million AUD | 38.72% |
| 2021 Q2 | -3.8 Million AUD | 0.0% |
| 2021 Q4 | -3.78 Million AUD | 0.0% |
| 2021 FY | -7.59 Million AUD | -101.94% |
| 2020 FY | -3.75 Million AUD | 16.32% |
| 2020 Q4 | -4.19 Million AUD | 0.0% |
| 2020 Q2 | 436 Thousand AUD | 0.0% |
| 2019 Q2 | 407 Thousand AUD | 0.0% |
| 2019 Q4 | -2.84 Million AUD | 0.0% |
| 2019 FY | -4.49 Million AUD | -5447.62% |
| 2018 Q2 | 459 Thousand AUD | 0.0% |
| 2018 FY | 84 Thousand AUD | -99.59% |
| 2018 Q4 | -375 Thousand AUD | 0.0% |
| 2017 Q2 | 13.2 Million AUD | 0.0% |
| 2017 FY | 20.55 Million AUD | -21.35% |
| 2017 Q4 | 7.35 Million AUD | 0.0% |
| 2016 FY | 26.13 Million AUD | 9.81% |
| 2016 Q2 | 16.73 Million AUD | 0.0% |
| 2016 Q4 | 9.4 Million AUD | 0.0% |
| 2015 Q2 | 13.02 Million AUD | 0.0% |
| 2015 Q4 | 10.77 Million AUD | 0.0% |
| 2015 FY | 23.8 Million AUD | -53.58% |
| 2014 FY | 51.27 Million AUD | 241.48% |
| 2014 Q4 | 9.66 Million AUD | 0.0% |
| 2014 Q2 | 41.61 Million AUD | 0.0% |
| 2013 FY | 15.01 Million AUD | 75.91% |
| 2013 Q4 | 11.19 Million AUD | 0.0% |
| 2013 Q2 | 4.04 Million AUD | 0.0% |
| 2012 Q3 | 2.13 Million AUD | 0.0% |
| 2012 FY | 8.53 Million AUD | -90.14% |
| 2012 Q2 | 2.13 Million AUD | -90.14% |
| 2012 Q1 | 21.64 Million AUD | 0.0% |
| 2012 Q4 | - AUD | -100.0% |
| 2011 Q4 | - AUD | -100.0% |
| 2011 FY | 86.59 Million AUD | 63.41% |
| 2011 Q1 | 13.24 Million AUD | 0.0% |
| 2011 Q2 | 21.64 Million AUD | 63.41% |
| 2011 Q3 | 21.64 Million AUD | 0.0% |
| 2010 Q4 | - AUD | -100.0% |
| 2010 Q1 | 162.5 Thousand AUD | 0.0% |
| 2010 Q2 | 13.24 Million AUD | 8052.46% |
| 2010 Q3 | 13.24 Million AUD | 0.0% |
| 2010 FY | 52.99 Million AUD | 8052.46% |
| 2009 Q1 | 1.12 Million AUD | 0.0% |
| 2009 FY | 650 Thousand AUD | -83.08% |
| 2009 Q2 | 162.5 Thousand AUD | -85.54% |
| 2009 Q4 | - AUD | -100.0% |
| 2009 Q3 | 162.5 Thousand AUD | 0.0% |
| 2008 Q4 | - AUD | -100.0% |
| 2008 Q2 | 1.12 Million AUD | 55.2% |
| 2008 Q1 | 724.25 Thousand AUD | 0.0% |
| 2008 FY | 3.84 Million AUD | 32.59% |
| 2008 Q3 | 1.12 Million AUD | 0.0% |
| 2007 Q4 | - AUD | -100.0% |
| 2007 Q2 | 724.25 Thousand AUD | 460.35% |
| 2007 Q1 | 129.25 Thousand AUD | 0.0% |
| 2007 Q3 | 724.25 Thousand AUD | 0.0% |
| 2007 FY | 2.89 Million AUD | 460.35% |
| 2006 Q1 | 677.77 Thousand AUD | 0.0% |
| 2006 Q4 | - AUD | -100.0% |
| 2006 Q3 | 129.25 Thousand AUD | 0.0% |
| 2006 FY | 517 Thousand AUD | -80.93% |
| 2006 Q2 | 129.25 Thousand AUD | -80.93% |
| 2005 Q3 | 677.77 Thousand AUD | 0.0% |
| 2005 Q4 | - AUD | -100.0% |
| 2005 FY | 2.71 Million AUD | -16.96% |
| 2005 Q1 | 816.2 Thousand AUD | 0.0% |
| 2005 Q2 | 677.77 Thousand AUD | -16.96% |
| 2004 Q2 | 816.2 Thousand AUD | 337.46% |
| 2004 Q3 | 816.2 Thousand AUD | 0.0% |
| 2004 Q4 | - AUD | -100.0% |
| 2004 FY | 3.26 Million AUD | 337.46% |
| 2004 Q1 | 186.57 Thousand AUD | 0.0% |
| 2003 Q4 | 186.57 Thousand AUD | 0.0% |
| 2003 FY | 746.3 Thousand AUD | 36.33% |
| 2003 Q2 | 186.57 Thousand AUD | 36.33% |
| 2003 Q3 | 186.57 Thousand AUD | 0.0% |
| 2003 Q1 | 136.86 Thousand AUD | 0.0% |
| 2002 Q3 | 136.86 Thousand AUD | 0.0% |
| 2002 Q2 | 136.86 Thousand AUD | 0.0% |
| 2002 Q4 | 136.86 Thousand AUD | 0.0% |
| 2002 FY | 547.44 Thousand AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AdAlta Limited | 1.5 Million AUD | 185.151% |
| Actinogen Medical Limited | 9.93 Million AUD | 112.929% |
| AnteoTech Limited | 460.39 Thousand AUD | 378.89% |
| Argenica Therapeutics Limited | 2.59 Million AUD | 149.424% |
| Arovella Therapeutics Limited | -25.97 Thousand AUD | -4842.454% |
| Anatara Lifesciences Ltd | -748.91 Thousand AUD | -71.449% |
| Alterity Therapeutics Limited | 3.8 Million AUD | 133.745% |
| Amplia Therapeutics Limited | 4.01 Million AUD | 132.014% |
| Avecho Biotechnology Limited | -43.79 Thousand AUD | -2831.842% |
| Bio-Gene Technology Limited | -301.44 Thousand AUD | -325.943% |
| Biome Australia Limited | 7.66 Million AUD | 116.741% |
| Biotron Limited | -40.49 Thousand AUD | -3070.527% |
| Botanix Pharmaceuticals Limited | -6.55 Million AUD | 80.402% |
| BTC Health Limited | 16.36 Thousand AUD | 7948.411% |
| Chimeric Therapeutics Limited | 7.45 Million AUD | 117.226% |
| CSL Limited | 15.28 Billion AUD | 100.008% |
| Clarity Pharmaceuticals Ltd | 11.5 Million AUD | 111.159% |
| Clinuvel Pharmaceuticals Limited | 78.09 Million AUD | 101.644% |
| Cynata Therapeutics Limited | 2.31 Million AUD | 155.449% |
| Dimerix Limited | 583.47 Thousand AUD | 320.06% |
| EZZ Life Science Holdings Limited | 50.94 Million AUD | 102.52% |
| Hexima Limited | - AUD | Infinity% |
| Island Pharmaceuticals Limited | 1.25 Million AUD | 202.591% |
| Immuron Limited | 3.33 Million AUD | 138.48% |
| Immutep Limited | 1.44 Million AUD | 188.926% |
| Imugene Limited | -5.83 Million AUD | 78.013% |
| Invex Therapeutics Ltd | 1.21 Million AUD | 205.918% |
| Memphasys Limited | 1606.00 AUD | 80050.187% |
| Nanollose Limited | -348.95 Thousand AUD | -267.959% |
| Neuren Pharmaceuticals Limited | 205.17 Million AUD | 100.626% |
| Noxopharm Limited | -534.81 Thousand AUD | -140.085% |
| NeuroScientific Biopharmaceuticals Limited | -91.33 Thousand AUD | -1305.783% |
| Nyrada Inc. | -5164.07 AUD | -24764.109% |
| Orthocell Limited | 3.68 Million AUD | 134.812% |
| PharmAust Limited | -1641.00 AUD | -78144.973% |
| Patrys Limited | 1.39 Million AUD | 192.098% |
| Paradigm Biopharmaceuticals Limited | 56.81 Thousand AUD | 2360.086% |
| Proteomics International Laboratories Limited | -1.12 Million AUD | -14.317% |
| Prescient Therapeutics Limited | 3.71 Million AUD | 134.587% |
| PYC Therapeutics Limited | 22.05 Million AUD | 105.821% |
| Race Oncology Limited | 1.38 Million AUD | 192.38% |
| Radiopharm Theranostics Limited | -21.3 Million AUD | 93.974% |
| Recce Pharmaceuticals Ltd | -366.76 Thousand AUD | -250.085% |
| Starpharma Holdings Limited | 7.65 Million AUD | 116.769% |
| Telix Pharmaceuticals Limited | 308.5 Million AUD | 100.416% |
| Tissue Repair Ltd | 150.51 Thousand AUD | 953.094% |
| Zelira Therapeutics Limited | 10.28 Thousand AUD | 12585.414% |